Eveliqure's diarrhoea vaccine to advance towards clinical trials supported by significant Horizon2020 award.

€8.6M grant to support first-in-man studies of its proprietary ShigETEC vaccine.

The €8.6M grant has been awarded to the SHIGETECVAX project, an international consortium of world-leading vaccine organizations - The European Vaccine Initiative (consortium leader), EveliQure Biotechnologies, University of Gothenburg, International Centre for Diarrhoeal Disease Research Bangladesh (icddr,b) and PATH.

The project will run for 5 years and will cover the manufacture and formulation of clinical trial material and Phase 1 safety and  immunogenicity studies in two different populations, adults in Europe and children in Bangladesh.

Read full story.